Biological marker And NotWalter P. Maksymowych

List of bibliographic references

Number of relevant bibliographic references: 4.

Ident.	Authors (with country if any)	Title
000D20	Maarten Boers [Pays-Bas] ; John R. Kirwan [Royaume-Uni] ; George Wells [Canada] ; Dorcas Beaton [Canada] ; Laure Gossec [France] ; Maria-Antonietta D'Agostino [France] ; Philip G. Conaghan [Royaume-Uni] ; Clifton O. Iii Bingham [États-Unis] ; Peter Brooks [Australie] ; Robert Landewe [Pays-Bas] ; Lyn March [Australie] ; Lee S. Simon [États-Unis] ; Jasvinder A. Singh [États-Unis] ; Vibeke Strand [États-Unis] ; Peter Tugwell [Canada]	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0
000F60	Benicio N. Frey [Canada] ; Ana C. Andreazza [Canada] ; Josselin Houenou [France] ; Stéphane Jamain [France] ; Benjamin I. Goldstein [Canada] ; Mark A. Frye [États-Unis] ; Marion Leboyer [France] ; Michael Berk [Australie] ; Gin S. Malhi [Australie] ; Carlos Lopez-Jaramillo [Colombie] ; Valerie H. Taylor [Canada] ; Seetal Dodd [Australie] ; Sophia Frangou [Royaume-Uni] ; Geoffrey B. Hall [Canada] ; Brisa S. Fernandes [Brésil] ; Marcia Kauer-Sant'Anna [Brésil] ; Lakshmi N. Yatham [Canada] ; Flavio Kapczinski [Brésil] ; L. Trevor Young [Canada]	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force
000F61	D. W. Miles [Royaume-Uni] ; S. L. De Haas [Suisse] ; L. Y. Dirix [Belgique] ; G. Romieu [France] ; A. Chan [Australie] ; X. Pivot [France] ; P. Tomczak [Pologne] ; L. Provencher [Canada] ; J. Cortes [Espagne] ; P. R. Delmar [Suisse] ; S. J. Scherer [États-Unis]	Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
001166	C. Twelves [Royaume-Uni] ; W. Scheithauer [Autriche] ; J. Mckendrick [Australie] ; J.-F. Seitz [France] ; G. Van Hazel [Australie] ; A. Wong [Canada] ; E. Diaz-Rubio [Espagne] ; F. Gilberg [Suisse] ; J. Cassidy [Royaume-Uni]	Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024